Novavax Inc. (NVAX)
Novavax (NVAX) Laps the Stock Market: Here's Why
In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID, combination vaccine development and early oncology research.
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference
Novavax NASDAQ: NVAX outlined its strategy to expand the use of its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances, with management highlighting progress in infectious disease vaccines and early oncology work at the Cantor Healthcare Conference.
Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
Retail traders are treating Novavax as a cancer-vaccine play today, but the price action shows a single-name bid rather than a sector move. Novavax (NASDAQ:NVAX) stock is up 6% to $9.90 in midday trading.
Novavax Stock Pulls Back After Milestone Vaccine Success
Drug stock Novavax Inc (NASDAQ:NVAX) is trading 2.8% lower at $9.18 this afternoon, pulling back from yesterday's surge to six-week highs.
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.
Novavax Q2 Earnings Call Highlights
Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant platform and continued cost reductions.
Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript
Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to earnings of $0.62 per share a year ago.
Are Medical Stocks Lagging Novavax (NVAX) This Year?
Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Novavax: The Beaten-Down COVID-19 Darling
Novavax is significantly undervalued post-COVID, with a current enterprise value around $716 million and a promising pipeline led by Matrix-M. NVAX's Matrix-M adjuvant is a core value driver, validated by major partnerships with Sanofi and Pfizer, offering substantial milestone and royalty upside. Revenue is now primarily driven by licensing and royalties, with product sales from Nuvaxovid declining sharply; partnership dependence is a key risk.
